First-line romosozumab ‘safe’ in severe osteoporosis
The US Endocrine Society has added the agent to its guidelines for therapy for postmenopausal women
Postmenopausal women with severe osteoporosis can safely be prescribed the anabolic drug romosozumab as a first-line therapy, according to updated guidance from the US Endocrine Society.
The peak body made the decision to add the drug to its guidelines after reviewing a meta-analysis and two large clinical trials assessing its efficacy against placebo and the osteoporosis drug alendronate.
